Evidence map›Paper›PMID 38676861›Full record

ArticleJournal of clinical immunology2024

Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses.

Wilhelm Hedin, Peter Bergman, Mily Akhirunessa, Sandra Söderholm, Marcus Buggert, Tobias Granberg, Sara Gredmark-Russ, C I Edvard Smith, Aleksandra Pettke, Emilie Wahren Borgström

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Tick-Borne Encephalitis in the 21Le infezioni in medicina · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wilhelm HedinDepartment of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Peter BergmanDepartment of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Mily AkhirunessaDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
Sandra SöderholmDepartment of Microbiology, Public Health Agency of Sweden, Solna, Sweden.
Marcus BuggertDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
Tobias GranbergDepartment of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
Sara Gredmark-RussDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
C I Edvard SmithDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Aleksandra PettkeDepartment of Microbiology, Public Health Agency of Sweden, Solna, Sweden.
Emilie Wahren BorgströmDepartment of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden. emilie.wahren-borgstrom@regionstockholm.se.
Karolinska University Hospital · SEKarolinska Institutet · SEPublic Health Agency of Sweden · SE

Funding

ALF, Sweden FoUI-954108Center for Innovative Medicine FoUI-975806Vetenskapsrådet 2022-00956
6 · The paper itself

Abstract

purposeA patient with X-linked agammaglobulinemia (XLA) and severe tick-borne encephalitis (TBE) was treated with TBE virus (TBEV) IgG positive plasma. The patient's clinical response, humoral and cellular immune responses were characterized pre- and post-infection.

methodsELISA and neutralisation assays were performed on sera and TBEV PCR assay on sera and cerebrospinal fluid. T cell assays were conducted on peripheral blood the patient and five healthy vaccinated controls.

resultsThe patient was admitted to the hospital with headache and fever. He was not vaccinated against TBE but receiving subcutaneous IgG-replacement therapy (IGRT). TBEV IgG antibodies were low-level positive (due to scIGRT), but the TBEV IgM and TBEV neutralisation tests were negative. During hospitalisation his clinical condition deteriorated (Glasgow coma scale 3/15) and he was treated in the ICU with corticosteroids and external ventricular drainage. He was then treated with plasma containing TBEV IgG without apparent side effects. His symptoms improved within a few days and the TBEV neutralisation test converted to positive. Robust CD8

conclusionTBEV IgG-positive plasma given to an XLA patient with TBE without evident adverse reactions may have contributed to a positive clinical outcome. Similar approaches could offer a promising foundation for researching therapeutic options for patients with humoral immunodeficiencies. Importantly, a robust CD8

Indexed as

AgammaglobulinemiaAntibodies, ViralEncephalitis, Tick-BorneEncephalitis Viruses, Tick-BorneGenetic Diseases, X-LinkedImmunoglobulin GT-LymphocytesAdultHumansImmunization, PassiveMaleTreatment OutcomeAntibodies, ViralImmunoglobulin GCD8+ T cellsimmunodeficiencyneutralising antibodiestetramerstick-borne encephalitisX-linked agammaglobulinemia

Identifiers

PMID38676861
PMCPMC11055791
OpenAlexW4395701798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.